Herbert Yu, MD, PhD, MSc

Herbert Yu, MD, PhD, MSc

This email address is being protected from spambots. You need JavaScript enabled to view it. | (808) 564-5910

Full Member, Population Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaiʻi Cancer Center

Academic Appointment(s):
Professor (Researcher), University of Hawaiʻi Cancer Center
Adjunct Professor of Epidemiology, Yale University School of Public Health

MD (Preventive Medicine), Shanghai Medical University
PhD (Clinical Biochemistry), University of Toronto
MSc (Epidemiology), University of Toronto

Research Focus

Dr. Yu is a molecular epidemiologist, and his research focuses on gene-environment interaction in cancer development and molecular changes in tumor progression and disease prognosis. Being trained both in population science and laboratory research, Dr. Yu has extensive experience in conducting epidemiological studies and clinical investigations. He has completed numerous research projects focusing on a number of cancer sites, including the breast, ovary, endometrium, liver, lung, pancreas and prostate. His research covers a wide range of topics, including dietary habit, nutrient intake, physical activity, genetic susceptibility, sex steroid hormones, mitogenic growth factors, gene-environment interaction, genotype-phenotype interplay, lifestyle influences on epigenetic regulation, and biomarkers for disease prognosis and treatment response. Recently, Dr. Yu's research addresses changes in DNA methylation in relation to tumor progression and their clinical applications. He has investigated DNA methylation in tumor suppressor genes and DNA repair genes, methylator phenotype in tumor progression, methylation pattern in regulation of alternative expression in multiple promoters, tumorigenic effects of microRNAs and long non-coding RNAs, and impacts of physical activity and obesity on epigenetic regulation. He has been involved in several NIH-funded clinical and epidemiological research projects to study molecular and genetic factors in association with cancer risk and tumor progression, including genome-wide association studies. Currently, he is a principal investigator of population-cased case-control studies of hepatocellular carcinoma and endometrial cancer. He also conducts two clinical studies to investigate genetic and molecular markers in relation to clinical and pathological features of breast and ovarian cancers as well as survival outcomes of patients diagnosed with these cancers.

Selected Publications

Wang Z, Katsaros D, Biglia N, Shen Y, Loo L, Yu X, Lin H, Fu Y, Chu WM, Fei P, Ni Y, Jia W, Deng X, Qian B, Yu H. (2018). ER-alpha upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-kB in breast cancer. Breast Cancer Res Treat; 175: 353-368. PMID30830488. PMCID: PMC6534447. doi:10.1007/s10549-05108-5.

Webb PM, Na R, Weiderpass E, Adami HO, Anderson KE, Bertrand KA, Botteri E, Brasky TM, Brinton LA, Chen C, Doherty JA, Lu, L, McCann SE, Moysich KB, Olson S, Petruzella S, Palmer JR, Prizment AE, Schairer C, Setiawan VW, Spurdle AB, Trabert B, Wentzensen N, Wilkens L, Yang HP, Yu H, Risch HA, Jordan SJ. (2018). Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium. Annals of Oncology; 30: 310-316. PMID: 30566587. PMCID: PMC6386026. doi:10.1093/annonc/mdy541.

Walsh N, Zhang H, Hyland P, Yang Q, Mocci E, Zhang M, Childs EJ, Collins I, Wang Z, Arslan AA, Beane-Freeman L, …, Yu H, … et al. (2018). Agnostic pathway/gene set analysis of genome-wide association data identifies novel associations for pancreatic cancer. J Natl Cancer Inst; Dec 12. doi:10.1093/jnci/djy155. PMID: 30541042.

Mao C, Wang X, Liu Y, Wang M, Yan B, Jiang Y, Shi Y, Shen Y, Liu X, Lai W, Yang R, Xiao D, Cheng Y, Liu S, Zhou H, Cao Y, Yu W, Muegge K, Yu H, Tao Y. (2018). A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. Cancer Res; 78(13):3484-96. PMID: 29588351.

Wang Z, Katsaros D, Biglia N, Shen Y, Fu Y, Loo LW, Jia W, Obata Y, Yu H. (2018). High expression of long non-coding RNA MALAT1 in breast cancer is associated with poor relapse-free survival. Breast Cancer Res Treat; 171:261-271. PMID: 29845475.

Publication list via PubMed

Active Grants

H. Yu, Mishra, Li, Shetty, MPIs
National Cancer Institute
1 U01CA230690-01
"Pathway specific functional biomarkers for the early detection of liver cancer"
2018 - 2023

H. Yu, Program Co-Leader; R. Holcombe, PI
National Cancer Institute
University of Hawaiʻi Cancer Center CCSG
1997 - 2021